Scientists in a race to discover why the Universe exists
They are in a race for the answer with a separate team of Japanese scientists – who are several years ahead.
The current theories of astronomy can't explain why the planets stars and galaxies came into existence. Both teams are building detectors that study a sub-atomic particle called a neutrino in the hope of finding answers.
US scientists are hoping the answer lies deep underground, in the aptly named Deep Underground Neutrino Experiment (Dune).
The scientists travel 1,500 metres below the surface into three vast underground caverns. Such is the scale that construction crews and their bulldozers seem like small plastic toys by comparison.
Dune's science director Dr Jaret Heise describes the giant caves as "cathedrals to science".
Dr Heise has been involved the construction of these caverns for nearly ten years. They seal Dune off from the noise and radiation from the world above. Now, Dune is now ready for the next stage.
"We are poised to build the detector that will change our understanding of the Universe with instruments that will be deployed by a collaboration of 1,500 scientists who are eager to answer the question of why we exist," he says.
When the Universe was created two kinds of particles were created: matter – from which stars, planets and everything around us are made – and, in equal amounts, antimatter, matter's exact opposite.
Theoretically the two should have cancelled each other out, leaving nothing but a big burst of energy. And yet, here we – as matter – are.
Scientists believe that the answer to understanding why matter won – and we exist – lies in studying a particle called the neutrino and its antimatter opposite, the anti-neutrino.
They will be firing beams of both kinds of particles from deep underground in Illinois to the detectors at South Dakota, 800 miles away.
This is because as they travel, neutrinos and anti-neutrinos change ever so slightly.
The scientists want to find out whether those changes are different for the neutrinos and anti-neutrinos. If they are, it could lead them to the answer of why matter and anti-matter don't cancel each other out.
Dune is an international collaboration, involving 1,400 scientists from thirty countries. Among them is Dr Kate Shaw from Sussex University, who told me that the discoveries in store will be "transformative" to our understanding of the Universe and humanity's view of itself.
"It is really exciting that we are here now with the technology, with the engineering, with the computer software skills to really be able to attack these big questions," she said.
Half a world away, Japanese scientists are using shining golden globes to search for the same answers. In all their splendour, look like a temple to science. The scientists are building Hyper K - which will be a bigger and better version of their existing neutrino detector, Super K.
The Japanese-led team will be ready to turn on their neutrino beam in less than two years, several years earlier than the American project. Just like Dune, Hyper K is an international collaboration. Dr Mark Scott of Imperial College, London believes his team is in pole position to make one of the biggest ever discoveries about the origin of the Universe.
"We switch on earlier and we have a larger detector, so we should have more sensitivity sooner than Dune," he says.
Having both experiments running together means that scientists will learn more than they would with just one, but, he says, "I would like to get there first!"
But Dr Linda Cremonesi, of Queen Mary University of London, who works for the US project, says that getting there first may not give the Japanese-led team the full picture of what is really going on.
"There is an element of a race, but Hyper K does not have yet all of the ingredients that they need to understand if neutrinos and anti-neutrinos behave differently".
The race may be on, but the first results are only expected in a few years' time. The question of just what happened at the beginning of time to bring us into existence remains a mystery – for now.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
a day ago
- Business Wire
ClearStrand-ASD, First-of-Its-Kind Autism Screening Tool, Now Available in Japan
NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)-- LinusBio, a leader in precision exposome medicine, announced today that ClearStrand-ASD™, its biochemical autism screening test, is now available to patients and providers in Japan for research use through its partnership with YAC Bio. This milestone marks LinusBio's first international expansion and represents a significant step in the company's mission to enable earlier identification of autism spectrum disorder (ASD) globally. Today marks a transformational moment in our mission to make early autism screening accessible worldwide. Share ClearStrand-ASD requires only a strand of hair to detect molecular signatures associated with autism spectrum disorder. This innovative, non-invasive approach provides healthcare providers with an objective screening method that can help identify ASD risk as early as one month of age, allowing families to pursue intervention during the most crucial period of early development. "Today marks a transformational moment in our mission to make early autism screening accessible worldwide," said Dr. Manish Arora, Founder and CEO of LinusBio. "Japan represents our first step beyond U.S. borders, and we chose this market because of its sophisticated healthcare infrastructure and commitment to pediatric developmental care. Japanese families dealing with autism concerns will now have access to the same cutting-edge screening technology that has already helped multiple American families get answers earlier than ever before." The Japanese launch builds on ClearStrand-ASD's successful rollout across the United States, where it is now available in 49 states. YAC Bio will partner with hospital systems in Japan to facilitate the implementation of this first-of-its-kind biomarker test for autism. LinusBio's expansion into Japan is facilitated through its existing partnership with YAC Bio (part of Y.A.C. Holdings), the Japanese multinational that invested over 1 billion yen in the company. Beyond providing market access, Y.A.C. Holdings contributes manufacturing expertise and automation capabilities that support LinusBio's scaling efforts globally. "By combining the world's only hair-cutting robotics technology with the innovative hair exposome analysis developed by LinusBio in the United States, we have contributed to the development of the world's first biomarker screening test for autism spectrum disorder. Following its launch in the U.S., we are now offering this test in Japan through our group company, YAC Bio," said Takefumi Momose, President and CEO, Y.A.C. Holdings Co., Ltd. "We sincerely hope that this test will support individuals, families, and communities in Japan who are concerned about autism." The Japan availability of ClearStrand-ASD represents the first phase of LinusBio's international expansion strategy, with the company evaluating additional markets where ClearStrand-ASD could address unmet needs in early autism detection. About ClearStrand-ASD ClearStrand-ASD is a biochemical test intended to help health care providers rule out autism spectrum disorder (ASD) in children 1 to 48 months. The test analyzes a strand of hair to map the dynamic patterns of an individual's unique biological responses at a molecular level to environmental exposures over time and uses an algorithm to assess the likelihood of autism. It is not a genetic test and must be ordered by a licensed health care provider (Rx only). ClearStrand-ASD is performed at LinusBio's CLIA-certified laboratory (CLIA #31d2307499). For more information visit: About LinusBio LinusBio (Linus Biotechnology Inc.) is a patient-centric, breakthrough science precision exposome medicine company headquartered in New Jersey. The Company's program pipeline comprises precision exposome medicine biomarkers and target discovery across disease domains for which historically no molecular endpoints have been available in medical practice or for clinical trials, including CNS (autism spectrum disorder, amyotrophic lateral sclerosis), gastroenterology (inflammatory bowel disease), renal disease and oncology. LinusBio is actively exploring additional international partnerships to expand global access to its innovative diagnostic solutions. For more information, visit About Y.A.C. Holdings Y.A.C. Holdings is a Japan-based company specializing in developing, designing, and manufacturing mechatronics-related products. The company collaborates with LinusBio on hardware innovations to scale testing capacity, driving breakthroughs in robotics and laboratory automation.
Gizmodo
2 days ago
- Gizmodo
China Is Building an AI Robot Uterus, and Are We Just Basically ‘Dune' Now?
In a development that completely demolishes the line between robotics and reproductive science, China's Kaiwa Technology says it has introduced humanoid robots equipped with advanced artificial womb systems. What could possibly go wrong with this line of experimentation? Well, those of you who are Dune fans know exactly where this could theoretically go: a future filled with robots that take over humanity and have to be defeated and then outlawed in order to keep civilization going. But we should back up a little before we jump right to that. Let's first look a little closer at what Kaiwa says it has done thus far. It says it has a 'late stage' prototype that combines artificial intelligence with bioengineering and mimics the hormonal and physical processes of pregnancy. The robots have biosynthetic organs that the company claims are capable of simulating gestation in a controlled environment, including feeding an embryo or fetus via liquid nutrients. Kaiwa claims its womb-endowed robots will eventually retail for about $14,000, as SlashGear reports. How to Build an Artificial Womb Kaiwa has not disclosed whether it's running tests on biological material or with human eggs, sperm, or embryos. It also does not explain how an actual baby would be born. Well, the first and most obvious thing is that a robotic uterus could easily damage or terminate a fetus if it does not work correctly. Babies are not hydroponic, after all, and depend on a complex mixture of nutrients and signals from the highly complicated placenta, which is really the workhorse of pregnancy (aside from the pregnant person carrying the fetus). Creating an AI placenta would be much more of a Holy Grail in science than a robotic womb, because it grows, changes, and expands as the fetus develops and is far more delicate and difficult to replicate. Kaiwa did not respond to a request for comment. It has not said whether it is also developing a humanoid placenta or if that is already part of the robot uterus. 'This is a revolutionary step,' Kaiwa said in a statement. 'Our robots could help scientists explore the intricacies of gestation and, someday, provide alternatives to biological reproduction.' More worrying, there have been very few reports of any ethical vetting of what Kaiwa is using to test this new technology or how advanced it is. There is serious ethical debate over the future of human reproduction and how a robotic component would affect the relationships and ownership of embryos or children conceived or delivered that way, particularly in countries like the U.S., in which some states recognize embryos as property. The pros? If true and ethically vetted, this new technology could potentially open new avenues for infertility research and reproductive assistance. It could provide surrogacy at a much reduced cost of around $14,000 (the cost of the robot) for people who can't have a child, compared to a human surrogacy fee of about $100,000 to $200,000 in the U.S. The cons? The patchwork of laws applying to reproductive tech is a changing pattern depending on the country, the region, the governing bodies (like the European Union), cultural roles, religious rules, and the rights of parenthood and surrogates. Who would own each part of the process of creating a human fetus in a robot would have to be exhaustively studied and debated, and it would very likely fall short of most definitions of bioethical standards. Who then oversees that process and enforces its rules should there be infractions is a whole other ball of legal and ethical wax. The prospect of these robots being artificially intelligent raises another important issue. Super-sophisticated robots may eventually be granted personhood status, meaning they'd be protected under the same laws as human beings. And should these robots eventually feel and experience emotions in a manner similar to humans, that would introduce yet another layer of ethical and legal complexity. An artificial womb could also help human babies survive extreme prematurity and prevent serious complications like brain injuries, lung damage, or blindness. Indeed, advances in neonatal care may drive this technology forward, regardless of any overt attempt to create a robotic uterus. Conversely, critics worry about the potential misuse or dehumanization of the gestation process, noting that artificial wombs could lead to creating 'human-like entities' without full biological rights or moral considerations. 'Pregnancy is an extremely complex process, with each step being extremely delicate and critical,' Yi Fuxian, an obstetrician at the University of Wisconsin–Madison, told Newsweek. He said the robot is 'likely just a gimmick' and that synthetic gestation has caused problems in sheep, and that 'many health risks emerge at different ages, not to mention mental health issues.' Recent reporting has found that China and South Korea's tech sectors are watching the pregnancy robot saga closely. South Korea already has robots as 10% of its workforce. In January 2024, its Ministry of Trade, Industry, and Energy unveiled the Fourth Intelligent Robot Basic Plan, which will plow $2.24 billion in public and private investments by 2030 to advance automation across most business sectors. Countries with declining birth rates like Japan and South Korea may also be major marketplaces for a synthetic uterus. South Korea has declared its lack of babies a national emergency and has been attempting to lure people into becoming parents with a new ministry focused on providing housing, immigration, and other demographic markers that may be keeping people from having any or more children. The county has already invested more than $200 billion in fertility programs over the last 18 years, but thus far the birth rate has stayed low. Maybe having a government-subsidized pregnancy robot could change that.
Yahoo
3 days ago
- Yahoo
Firefly Aerospace eyes Japan rocket launches for Asia market
By Kantaro Komiya TOKYO (Reuters) -Firefly Aerospace is exploring an option to launch its Alpha rocket from Japan as the U.S. rocket maker expands its satellite launch services globally, a Japanese company operating a spaceport in the country's northern Hokkaido said on Monday. The plan could make Japan the second offshore launch site - and first in Asia - for Firefly, the Texas-based rival to Elon Musk's market leader SpaceX, which had its Nasdaq debut earlier this month and is preparing for an Alpha launch in Sweden. Space Cotan, operator of the Hokkaido Spaceport located about 820 km (510 mi) northeast of Tokyo, said it and Firefly signed a preliminary agreement to study the feasibility of launching the small-lift rocket Alpha from there. Launching Alpha from Japan "would allow us to serve the larger satellite industry in Asia and add resiliency for U.S. allies with a proven orbital launch vehicle," Adam Oakes, Firefly's vice president of launch, said in a statement published on Space Cotan's website. A feasibility study would be conducted to assess the regulatory hurdles, timeframe and investments for a launch pad for Alpha in Hokkaido, said Space Cotan spokesperson Ryota Ito. The plan would require a space technology safeguards agreement (TSA) between Washington and Tokyo that would allow American rocket launches in Japan, Ito added. The governments last year kicked off the negotiations but have not reached an agreement. A U.S.-Sweden TSA signed in June cleared the path for Firefly's launches from the Arctic. Four of Firefly's six Alpha flights since 2021 have ended in failure, most recently in April. While Japan's national space agency has launched rockets for decades, private rockets are nascent and most Japanese satellite operators rely on foreign options such as SpaceX's Falcon 9 or Rocket Lab's Electron. Previously, U.S. company Virgin Orbit aimed to use Japan's southwest Oita Airport for launches but the plan was scrapped after the firm went bankrupt in 2023. Colorado-based Sierra Space has an ongoing plan to land its spaceplane on Oita beyond 2027. Taiwanese firm TiSpace last month conducted what could be the first foreign launch in Hokkaido, but the suborbital flight failed within a minute. Japan's government is targeting 30 launches of Japanese rockets a year by the early 2030s and subsidises domestic enterprises such as Space One and Toyota-backed Interstellar Technologies.
